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From the Clinic 
•  Patients were recruited by a geriatrician at the family medicine clinic at PCOM 
•  An inclusion/ exclusion criteria was used to determine eligibility of a subject (Figure 1) 
•  The St. Louis University Mental Status (SLUMS) Exam was used to determine a 
subjects cognitive ability (Figure 2: see bottom for scoring key) 
•  Normal = Control Subject  
•  Dementia = AD Subject  
•  The University of Pennsylvania Smell Identification Test (UPSIT) was used to screen 
for any potential olfactory deficits in subjects (Figure 3) 
•  40 scratch and sniff odorants each of which is force- choice   
•  > 65 yo: Anosmia ≤18; Severe Microsmia 19 - 25  
•  Saliva was collected from subjects via passive drool (Salimetrics) 
•  Saliva was treated with protectant (Qiagen) for RNA stabilization and long-term storage  
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Care Office for helping us to identify patients to enroll for this study. We would 
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This pilot study is designed to  evaluate the cognitive status and biomarkers such 
as olfactory testing and miRNA from saliva in order to determine if these 
components of evaluation could be used to better predict an individual with AD 
from an age and gender matched control individual.  
•  Preliminary data indicate a correlation between the UPSIT and SLUMS exam 
•  Initial analysis shows a change in miRNA regulation between AD when 
compared to it’s control group 
•  Variability of miRNA expression levels between different age groups has been 
noted 
•  Therefore, the number of subjects in each age group needs to be 
increased to determine levels of variability between ages in miRNA 
expression  
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Figure 1: Inclusion/ Exclusion Criteria for 
Study Subjects 
Figure 2: SLUMS Exam 
SCORING
  HIGH SCHOOL EDUCATION LESS THAN HIGH SCHOOL EDUCATION
  27-30      Normal                      25-30
  21-26      MNCD*          20-24
   1-20     Dementia           1-19
    * Mild Neurocognitive Disorder
VAMC
SLUMS Examination
__/1
__/1
__/1
__/3
__/3
__/5
__/2
__/4
__/2
__/8
Name      Age
Is patient alert?     Level of education
1
1
1
1
2
0 1
0 1 1
2
2
1
1
2
2
2
2
1. What day of the week is it?
2. What is the year?
3. What state are we in?
4. Please remember these five objects. I will ask you what they are later.
Apple Pen Tie House Car
5. You have $100 and you go to the store and buy a dozen apples for $3 and a tricycle for $20.
How much did you spend?
How much do you have left?
6. Please name as many animals as you can in one minute.
0-4 animals   5-9 animals    10-14 animals 15+ animals
7. What were the five objects I asked you to remember? 1 point for each one correct.
8. I am going to give you a series of numbers and I would like you to give them to me backwards.
For example, if I say 42, you would say 24.
87 649 8537
9. This is a clock face. Please put in the hour markers and the time at
ten minutes to eleven o’clock.
Hour markers okay
Time correct
10. Please place an X in the triangle.
Which of the above figures is largest?
11.  I am going to tell you a story. Please listen carefully because afterwards, I’m going to ask you
some questions about it.
Jill was a very successful stockbroker. She made a lot of money on the stock market. She then met
Jack, a devastatingly handsome man. She married him and had three children. They lived in Chicago.
She then stopped work and stayed at home to bring up her children. When they were teenagers, she
went back to work. She and Jack lived happily ever after.
What was the female’s name? What work did she do?
When did she go back to work? What state did she live in?
TOTAL SCORE
SH Tariq, N Tumosa, JT Chibnall, HM Perry III, and JE Morley. The Saint Louis University Mental Status (SLUMS) Examination for Detecting Mild Cognitive
Impairment and Dementia is more sensitive than the Mini-Mental Status Examination (MMSE) - A pilot study. J am Geriatri Psych (in press).
2 3
Questions about this assessment tool? E-mail aging@slu.edu.
Figure 3: Sample Page of UPSIT 
AD	   Control	  
Figure 4: Line Graph and Chart showing UPSIT scores compared to SLUMS scores for 12 
subjects. AD Subjects scored below 20 in both the UPSIT and SLUMS exam. Control Subjects 
scored above a 24 in the SLUMS exam and above 18 on the UPSIT. 
Subject	   SLUMS	  Score	  	  UPSIT	  Score	  	  
AD	   2	   11	  
AD	   3	   16	  
AD	   6	   15	  
AD	   8	   12	  
AD	   13	   20	  
AD	   13	   16	  
AD	   15	   18	  
AD	   20	   15	  
AD	   20	   9	  
Control	   24	   18	  
Control	   25	   28	  
Control	   27	   38	  
Control	   28	   24	  
Control	   29	   34	  
Figure 5: Chart showing the layout of the Human Inflammatory Response & Autoimmunity Qiagen miScript 
miRNA PCR Array and all of the miRNAs that are being analyzed and compared in AD and Control Subjects 
Figure 6: Clustergram created from the Human Inflammatory Response & 
Autoimmunity Qiagen miScript miRNA PCR Array of 12 patients in triplicate. 
The expression levels shown are determined by the CT value.  
A.	   Age	   Sex	   SLUMS	   Smell	  Test	  
Control	   80	   Female	   29	   34	  
AD	   80	   Female	   2	   11	  
Figure 7: 80 year old Females  (AD vs. Control) 
A: SLUMS and UPSIT Scores 
B: Heat Map representing the fold change in each miRNA of the AD 
subject when normalized to the control 
C: Scatterplot showing the number of miRNAs that are over and 
under expressed in the AD subject (Group 1) when normalized to the 
control 
D: Clustergram demonstrating the gene expression levels for each 
individual miRNA calculated by the CT value (Group 1 = AD Subject) 
A.	   Age	   Sex	   SLUMS	   Smell	  Test	  
Control	   90	   Female	   24	   18	  
AD	   90	   Female	   8	   12	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Figure 8: 90 year old Females  (AD vs. Control) 
A: SLUMS and UPSIT Scores 
B: Heat Map representing the fold change in each miRNA of the AD 
subject when normalized to the control 
C: Scatterplot showing the number of miRNAs that are over and 
under expressed in the AD subject (Group 1) when normalized to the 
control 
D: Clustergram demonstrating the gene expression levels for each 
individual miRNA calculated by the CT value (Group 1 = AD Subject) 
B.	  
C.	  
D.	  
To the Lab 
•  miRNA extraction with Spike In-Control 
•  Spike In-Control used to determine the reliability of the extraction 
•  cDNA for samples and a standard curve transcribed (Qiagen miScript II RT Kit) and a 
RT-PCR was done to determine recovery of Spike-In Control  
•  cDNA from samples used to run a pre-loaded Human Inflammatory Response & 
Autoimmunity Qiagen miScript miRNA PCR Array using the StepOnePlus™ Real-Time 
PCR System (Applied Biosystems™ ThermoFisher Scientific) 
•  The miScript Primer Assay for C. elegans miR-39 detects the miRNeasy Serum/Plasma 
Spike-In Control and this is used as a control (Figure 5: H1and H2 in array) 
•  Qiagen analytical program was used to analyze data (generate clustergrams and heat 
maps)  from miRNA array to determine expression results from AD subjects in 
comparison to controls; quantification using the ΔΔCT method of relative quantification.   
 
Immune	  Response	  &	  Autoimmunity	  miScript	  miRNA	  PCR	  Array	  Layout	  	  
	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   11	   12	  
A	   hsa-­‐let-­‐7a-­‐5p	   hsa-­‐let-­‐7b-­‐5p	   hsa-­‐let-­‐7c-­‐5p	   hsa-­‐let-­‐7d-­‐5p	   hsa-­‐let-­‐7e-­‐5p	   hsa-­‐let-­‐7f-­‐5p	   hsa-­‐let-­‐7g-­‐5p	   hsa-­‐let-­‐7i-­‐5p	   hsa-­‐miR-­‐101-­‐3p	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   hsa-­‐miR-­‐19a-­‐3p	   hsa-­‐miR-­‐19b-­‐3p	   hsa-­‐miR-­‐202-­‐3p	   hsa-­‐miR-­‐20a-­‐5p	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   hsa-­‐miR-­‐21-­‐5p	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D	   hsa-­‐miR-­‐23b-­‐3p	   hsa-­‐miR-­‐29a-­‐3p	   hsa-­‐miR-­‐29b-­‐3p	   hsa-­‐miR-­‐29c-­‐3p	   hsa-­‐miR-­‐300	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   hsa-­‐miR-­‐30c-­‐5p	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   hsa-­‐miR-­‐424-­‐5p	  
F	   hsa-­‐miR-­‐449a	   hsa-­‐miR-­‐449b-­‐5p	   hsa-­‐miR-­‐454-­‐3p	   hsa-­‐miR-­‐497-­‐5p	   hsa-­‐miR-­‐511-­‐5p	   hsa-­‐miR-­‐513b-­‐5p	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   hsa-­‐miR-­‐520e	   hsa-­‐miR-­‐524-­‐5p	   hsa-­‐miR-­‐543	  
G	   hsa-­‐miR-­‐545-­‐3p	   hsa-­‐miR-­‐548c-­‐3p	   hsa-­‐miR-­‐548d-­‐3p	  hsa-­‐miR-­‐548e-­‐3p	   hsa-­‐miR-­‐590-­‐5p	   hsa-­‐miR-­‐607	   hsa-­‐miR-­‐655-­‐3p	   hsa-­‐miR-­‐656-­‐3p	   hsa-­‐miR-­‐875-­‐3p	   hsa-­‐miR-­‐9-­‐5p	   hsa-­‐miR-­‐93-­‐5p	   hsa-­‐miR-­‐98-­‐5p	  
H	   cel-­‐miR-­‐39-­‐3p	   cel-­‐miR-­‐39-­‐3p	   SNORD61	   SNORD68	   SNORD72	   SNORD95	   SNORD96A	   RNU6-­‐6P	   miRTC	   miRTC	   PPC	   PPC	  
	   	   	   	   	   	   	   	   	   	   	   	   	  
	   	   	   	  	   Key	   	   	   	  
	   	   	   	  	   miScript	  Primer	  Assay	  for	  a	  pathway/	  disease/	  func/onally	  related	  mature	  miRNA	   	   	   	  
	   	   	   	  	   C.	  elegans	  miR-­‐39	  miScript	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  be	  used	  as	  an	  alterna/ve	  normalizer	  for	  array	  data	   	   	   	  
	   	   	   	  	   Assay	  for	  a	  different	  snoRNA/	  snRNA	  that	  can	  be	  used	  as	  a	  normaliza/on	  control	  for	  the	  array	  data	   	   	   	  
	   	   	   	  	   miRTC	  miScript	  Primer	  Assays	  for	  assessment	  of	  reverse	  transcrip/on	  performance	   	   	   	  
	   	   	   	  	   Posi/ve	  PCR	  Controls	  for	  assessment	  of	  PCR	  performance	   	   	   	  
B.	  
C.	   D.	  
ABSTRACT 
INTRODUCTION 
Alzheimer’s Disease (AD) incidence increases with age and is considered to be 
one of the most common causes of dementia by effecting 5.4 million people over 
the age of 65 in the US (Alzheimer’s & Dementia, 2012; Balin and Hudson, 
2014). The neuropathology in, both early-onset and late-onset, AD is 
characterized by modified tau proteins forming neurofibrillary tangles (NFT) and 
neurophil threads (NT), as well as, deposits of β-amyloid peptide (Aβ) that lead to 
the formation of neuritic senile plaques (NSP). However the biological process in 
late-onset AD leading to this pathology is still unknown (Balin and Hudson, 
2014; Lippa et al, 1996). In addition, there are many discrepancies when 
diagnosing late-onset AD (oppose to other forms of dementia), which is also 
attributed to by the limited availability of both invasive and non-invasive 
procedures to confirm the neuropathology that is known to be a signature of AD 
(Burgos et al, 2014; Jin et al 2013). 
A small, endogenous non-coding RNA that is known to regulate post-
transcriptional gene expression, referred to as miRNA, can be found in biofluids 
outside of the brain and can be associated with neurodegenerative diseases 
(Burgos et al, 2014; Jin et al, 2013). Recent studies have identified dysregulated 
miRNAs in cerebral spinal fluid and blood serum data from AD patients that may 
be useful in addressing disease progression (Burgos et al, 2014). Other studies 
have confirmed that saliva can be used to identify miRNA profiles in disease 
pathologies (Bonne and Wong, 2012; Park et al 2009). However, the miRNA 
profiles correlated with AD have yet to be examined via saliva. If in fact, 
dysregulated miRNAs can be found in saliva, similar to blood serum and CSF, 
this could lead to the development of a non-invasive procedure with the potential 
to explore the neuropathology directly associated with AD and a quantitative 
diagnosis. 
In addition to dysregulated miRNA that has been observed in AD, olfactory 
deficits have been noted. For AD a deficit in smell has not only been associated 
with cognitive impairment, but has been used as a model to predict cognitive 
decline (Devanand et al, 2015). In this study it is hypothesized that subjects with 
AD will demonstrate a difference in the miRNA expression profiles in saliva and 
a decreased sense of smell compared to similar age matched controls.  
Introduction: Recent studies identified dysregulated miRNAs in cerebral spinal 
fluid and serum from AD patients (Burgos et al, 2014). Other studies have 
identified miRNA profiles in disease pathologies from saliva (Bonne and Wong, 
2012; Park et al, 2009), suggesting that this may also be possible in AD. This 
could lead to a non-invasive procedure that correlates biomarkers directly to AD 
for a quantitative diagnosis of this disease.  
Objective: To evaluate the potential for using a combination of SLUMS testing, 
smell testing and miRNA isolated from saliva as biomarkers in the diagnosis of 
AD.   
Methods:  Subjects first were evaluated using a St. Louis University Mental 
Status (SLUMS) exam, followed by collection of saliva and administration of the 
University of Pennsylvania Smell Identification test. Saliva was treated with 
protectant for stabilization of miRNA that was subsequently extracted from AD 
and control subjects after being treated with a Spike In-Control, which was used 
to determine the reliability of the extraction. Analysis of the miRNA samples was 
performed to determine recovery of Spike-In Control by RT-PCR using a 
standard curve.  A Qiagen analytical program was used to analyze data from 
inflammatory response and autoimmunity miRNA arrays to determine expression 
results from AD subjects in comparison to controls.   
Results: Individuals with low SLUMS scores appeared to also have low smell 
test scores.  miRNA analysis for inflammation between age and gender matched 
individuals showed a significant difference in the fold change between AD and 
controls. miRNA analysis is ongoing to determine if there is a correlation 
between fold regulation of miRNA with SLUMS and Smell Tests.  
Conclusion: Evaluation of saliva for miRNA was successful. Preliminary data 
indicate that there is correlation between the SLUMS exam and smell test, as well 
as, a change in miRNA regulation between AD when compared to it’s control 
group. Analysis of specific miRNA changes is ongoing.   
METHODS (CONT.) 
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Patient'Contact'Information'to'Share'with'Researcher:'Patient'Nam :'___________________________________________________________________________________''Patient'Phone'#'_________________________________________________________________________________'Patient'Email:'___________________________________________________________________________________'
Evaluation!of!smell!and!miRNA!biomarkers!in!
Alzheimer’s!Disease!(AD)!
Eligible!
! 65'years'old'or'older''
• Age:'_________________________'
• Sex:'_________________________'
• Specified'Category'(must'be'1'of'the'3):'
! AgeHMatched'Control''
! History'of'AD'
! History'of'AD'&'TBI''
! No'exclusions'(healthy)'
! Mental'Status''
! Performed'By:'______________________________________'
! Date'Performed:____________________________________'
! SLUMS'Score:_______________________________________'
! FAST'Score:'_________________________________________'
! Other'Test__________________________Score:__________'
Ineligible!
! Under'65'years'old'
• Age:'_________________________'
• Sex:'_________________________'
! Exclusions'
! Chronic'diarrhea'
! Rheumatoid'Arthritis''
! Systemic'Autoimmune'Inflammatory'Disease''(e.g.'Chron’s'Disease)'
! Chronic'Steroid'Use''
! Parkinson’s'Disease'Vascular'Dementia''
! Extensive'Vascular'Disease''
! Normal'Pressure'Hydrocephalus'
! Familial'Neurodegenerative'Disorders'(e.g.'Familial'Alzheimer’s'Disease'and'FrontoHtemporal'Dementia)'
! NonHneurodegenerative'neurological'disorders''
! Diagnosed'Cancer'Fever'or'suspected'infection'
! Known'Hepatic'problems:''
o Any'clinically'significant'liver'function'studies''
! Known'Renal'Problems:'
! BUN:'any'clinically'significant'deviation'from'normal'
! Creatinine:'any'clinically'significant'deviation'from'normal''
o Creatinine'clearance'<'40'mL/min'
! ALT'>'1.5'UL'
Patient!#:________________________________!
Date:!________________________________!
!
